By Linda A. Johnson
The Associated Press
The arthritis drug Celebrex doesn't protect the stomach from dangerous bleeding ulcers as well as thought, a study suggests.
Celebrex, and similar anti-inflammatory drugs Vioxx and Bextra, are advertised as being safer for arthritis patients based on earlier research that found they caused fewer ulcers and other gastrointestinal complications than older anti-inflammatory medicines. Together, the three new drugs have annual sales exceeding $6 billion.
But their safety has been called into question recently. The new study, which focused on arthritis patients at high risk of recurrent ulcers, escalates the controversy involving Celebrex, showing nearly 10 percent of patients each year would develop another ulcer.
The study found the same thing for an older anti-inflammatory drug combined with ulcer medicine Prilosec, which doctors often give arthritis patients to protect their stomachs. In addition, neither treatment protected as many patients from dangerous kidney complications as past studies showed, the researchers said.
The Hong Kong researchers and some other experts said the results, while showing the treatments work the same, indicate more study is needed on preventing bleeding stomach ulcers in vulnerable older people who for years eased joint pain with nonsteroidal anti-inflammatory drugs, or NSAIDs.
"I think patients and doctors need to be aware ... there is a risk of gastrointestinal bleeding and there is a risk of renal toxicity," so high-risk patients should be monitored closely by their doctor, said Dr. John H. Klippel, medical director of the Arthritis Foundation.
A spokesman for Pharmacia Corp., which makes Celebrex, said the company interprets the findings as showing Celebrex reducing the risk of gastrointestinal complications in high-risk patients.
"It is our feeling that these findings should guide future research in the area," spokesman Paul Fitzhenry said Wednesday.
Representatives of AstraZeneca Pharmceuticals LP, which sells Prilosec, did not return calls Wednesday.
The study, reported in today's New England Journal of Medicine, included 287 patients who had a previous bleeding ulcer and so were at very high risk of developing another.
Half took the anti-inflammatory diclofenac together with Prilosec; half received Celebrex. It is one of three brand-name NSAIDs in a newer class called cox-2 inhibitors because they block the cox-2 enzyme. It produces chemicals called prostaglandins that cause pain and inflammation in the stomach as part of the body's repair process.
These drugs, which also include Vioxx and Bextra, do not block action of the cox-1 enzyme, which protects the lining of the stomach. Older NSAIDs such as diclofenac block both cox enzymes, and so can cause stomach irritation and exacerbate ulcers.
Complications from taking older anti-inflammatory drugs hospitalize about 107,000 Americans, and ulcer complications kill an estimated 16,500 each year.
Of the study patients receiving Celebrex, about 5 percent had recurrent bleeding during the six months of research, compared with about 6.5 percent for those getting diclofenac and Prilosec.
However, that equates to annual rates of about 9 percent and 11 percent, respectively, Dr. David Y. Graham of the Veterans Affairs Medical Center in Houston wrote in an accompanying editorial.
"The results were unexpected: Neither regimen provided a good or even acceptable level of protection from recurrent bleeding," Dr. David Y. Graham of the Veterans Affairs Medical Center in Houston wrote.
Both treatments did a good job in reducing pain and enabling patients to perform daily activities over the six-month experiment.
But about 25 percent of those in the Celebrex group and 31 percent in the diclofenac/Prilosec group suffered kidney complications, including high blood pressure and swollen ankles; about 6 percent in each group suffered life-threatening kidney failure.
Klippel said that shows doctors must monitor high-risk patients on these anti-inflammatory drugs for increased pain and bloody stools indicating an ulcer flareup. They also should watch for swelling in the extremities and elevated blood pressure - signs the kidneys can't excrete enough fluid.
"Physicians should avoid prescribing these drugs to patients with known kidney diseases, poorly controlled hypertension and heart failure," said the lead researcher, Dr. Francis K.L. Chan. "Previous studies reported a very low incidence of kidney side effects because they excluded patients with major medical illnesses."
Still, the study backs up the American College of Rheumatology's current guidelines for treating arthritis and gives doctors options, said Dr. Todd Stitik, associate professor of physical medicine and rehabilitation at University of Medicine and Dentistry of New Jersey in Newark.
For patients whose prescription plan covers the pricey cox-2 inhibitors, one less pill is more convenient and reduces chances of interactions with their other medicines, he said. For others, numerous generic anti-inflammatory and ulcer drugs are available.
Some arthritis patients can limit or avoid pain medications, Stitik noted, through treatments ranging from stretching and other exercise to weight loss, hot or cold packs and braces or splints.
College ready to sell concept
Implosion means lights out for Cinergy Field signs
West Virginia ticket has winning Powerball numbers
Shooter in 63rd homicide sought
Two men shot on Christmas night
Homicides match last year's 63
Teens' deaths a blow to schools
Volunteers spread cheer for holidays
U.S. soldiers celebrate Christmas with football, turkey
Celebrex not as protective against ulcers as was thought
Small cities use arts to boost economies
Humor causes Comair to cancel flight to CVG
Now broke, gambler sues Ind. casino
Organ off for $250K tuneup
Nor'easter delivers two ft. of snow to N.Y.
Cincinnati tax plan to cost county
Ohio congressional delegation sees much work ahead in 2003
3 arrested in slaying of 5 near Detroit
Nursing home resident wants to smoke indoors
Fourth-graders learn via interactive television
Howard: Some good news
Historical Society markers to honor Wilberforce, CSU
Tristate A.M. Report
Past meets future in creating image
North Carolina banks take new steps for protection
They're Bobs-bob-bobbin' along
Law requiring warnings to credit card users scrapped
Troubled airlines present additional challenge for FAA
As Linux advances, Microsoft alters message to lure customers
Smoker accepts $28 million in LA tobacco suit
Asian stocks offer little holiday cheer
Where 'close' counts
Get to it
Author turns to kids' books
Knip's eye view
Lawyer turned to guilty pleasure - comedy
It's still Christmas in 'July'
New stamp will depict Year of Ram
Top 10 lists
Group shapes TV's sexuality